Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma
PROICM 2019-03 MES
Phase 2 other active
Quick answer
Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma for Malignant Peritoneal Mesothelioma is a Phase 2 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Malignant Peritoneal Mesothelioma
- Phase
- Phase 2
- Modality
- other
- Status
- active